secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001193125-26-018704
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction
--------------------------------------------------------------------------------

- Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).
- Median OS 16.0 months vs. 11.9 months (4.1-month improvement); both dual primary endpoints met.
- NDA under FDA review with PDUFA date of July 11, 2026; MAA under EMA review.
- Relacorilant well-tolerated without increased safety burden; no biomarker selection required.
- Trial enrolled 381 patients across US, Europe, South Korea, Brazil, Argentina, Canada, Australia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526018704/0001193125-26-018704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312526018704/d96058d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-018704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer